Increases of vitreous monocyte chemotactic protein 1 and interleukin 8 levels in patients with concurrent hypertension and diabetic retinopathy

Retina

Volumn 31, Issue 9, 2011, Pages 1951-1957

  Wakabayashi, Yoshihiro ^a   Usui, Yoshihiko ^a   Okunuki, Yoko ^a   Kezuka, Takeshi ^a   Takeuchi, Masaru ^a   Iwasaki, Takuya ^a   Ohno, Atsushi ^a   Goto, Hiroshi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

chemokine; diabetic retinopathy; hypertension; interleukin 8; monocyte chemotactic protein 1; vitreous

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INSULIN; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN;

ADULT; AGE; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PROTEIN CONTENT; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL; VITRECTOMY; VITREOUS BODY;

ADULT; AGED; CHEMOKINE CCL2; CHEMOKINE CXCL10; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; HYPERTENSION; IMMUNOASSAY; INTERLEUKIN-8; MALE; MIDDLE AGED; MONOKINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 80053365122     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31820d3cee     Document Type: Article

References (36)

1. Frank RN. Diabetic retinopathy. N Engl J Med 2004;50:48-58.
2. Stanford MR. The pathogenesis of diabetic retinopathy. Br J Ophthalmol 2004;88:444-445.
3. Barouch FC, Miyamoto K, Allport JR, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 2000;41:1153-1158.
4. Joussen AM, Murata T, Tsujikawa A, et al. Leukocytemediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001;158:147-152.
5. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989;169:1485-1490.
6. Larsen CG, Anderson AO, Appella E, et al. The neutrophilactivating protein (NPA-1) is also chemotactic for T lymphocytes. Science 1989;243:1464-1466.
7. Capeans C, Rojas MV, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina 1998;18:546-550.
8. Elner SG, Strieter RM, Bian ZM, et al. Interferon-induced protein 10 and interleukin 8 C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol 1998;116: 1597-1601.
9. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258:1798-1801.
10. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348-27357.
11. Klein R, Klein BE, Moss SE, Cruickshanks KJ. TheWisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815.
12. UK Prospective Diabetes Study (UKPDS) group. Risk of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus. UKPDS 69. Arch Ophthalmol 2004;122:1631-1640.
13. Capers Q 4th, Alexander RW, Lou P, et al. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997;30:1397-1402.
14. Kim HY, Kang YJ, Song IH, et al. Upregulation of interleukin- 8/CXCL8 in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertens Res 2008;31:515-523.
15. Wakabayashi Y, Usui Y, Okunuki Y, et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina 2010;30:339-344.
16. The Hypertension Detection and Follow-up Program. Hypertension detection and follow-up program cooperative group. Prev Med 1976;5:207-215.
17. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertension Res 2006;29:S1-S106.
18. Wakabayashi Y, Usui Y, Okunuki Y, et al. Increased levels of monokine induced by interferon-g (Mig) in the vitreous of patients with diabetic retinopathy. Diabet Med 2008;25: 875-877.
19. Grunwald JE, Riva CE, Sinclair SF, et al. Laser Doppler velocimetry study of retinal circulation in diabetes mellitus. Arch Ophthalmol 1986;104:991-996.
20. Rassam SM, Patel V, Kohner EM. The effect of experimental hypertension on retinal vascular autoregulation in humans: A mechanism for the progression of diabetic retinopathy. Exp Physiol 1995;80:53-68.
21. Elner SG, Elner VM, Jaffe GJ, et al. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045-1053.
22. Mitamura Y, Takeuchi S, Matsuda A, et al. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica 2001; 215:415-418.
23. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116:73-79.
24. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000;68:1-8.
25. Yoshida S, Yoshida A, Ishibashi T, et al. Role of MCP-1 and MIP-1a in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization. J Leukoc Biol 2003;73:137-144.
26. Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Hypertension 1995;25:155-161.
27. Ishibashi M, Hiasa KI, Zhao Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocyte in hypertension-induced vascular inflammation and remodeling. Circ Res 2004;94:1203-1210.
28. Parissis JT, Korovesis S, Giazizoglou E, et al. Plasma profile of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlation with plasma endothelin-1. Inv J Cardiol 2002;83:13-21.
29. Wung BS, Cheng JJ, Chao YJ, Wang DL. Cyclic strain increases monocyte chemotactic protein-1 secretion in human endothelial cells. Am J Physiol 1996;270:1462-1468.
30. Okada M, Matsumori A, Ono K, et al. Cyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and activating factor/monocyte chemoattractant protein- 1 in human endothelial cells. Arterioscler Thromb Vasc Biol 1998;18:894-901.
31. Suzuma I, Hata Y, Clermont A, et al. Cyclic stretch and hypertension induced retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor- 2. Potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes 2001;50:444-454.
32. Lewis M, Abrams GW, Williams GA. Anterior hyaloidal fibrovascular proliferation after vitrectomy. Am J Ophthalmol 1987;104:607-613.
33. Funatsu H, Yamashita H, Ikeda T, et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 2002;133:537-543.
34. Nagai N, Izumi-Nagai K, Oike Y, et al. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kB pathway. Invest Ophthalmol Vis Sci 2007;48:4342-4350.
35. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB control trial of lisinopril in insulin-dependent diabetes mellitus. Lancet 1998;351:28-31.
36. The DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomized placebo-controlled trial. Lancet 2008;372:1385-1393.